Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Duration: March 1, 2018
to
present
General Issues: Pharmacy , Copyright/Patent/Trademark , Trade (Domestic & Foreign) , Health Issues
Spending: about $1,180,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
Related Foreign Entities:
Mylan N.V. (Hertfordshire, EN6 1AG, GBR); contribution to lobbying: $0; ownership 100%; Mylan Holdings Ltd. (Hertfordshire EN6 1AG, GBR); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Cristina Antelo
Legal Fellow, Senate Democratic Steering Committee
Lucia Alonzo
Leg. Correspondent/Policy Aide, Sen. Claire McCaskill
Mark Williams
Chief of Staff, Rep. Michael Conaway // Chief of Staff, Rep. Todd Rokita // Dep. Chief of Staff/Leg. Director, Rep. Sam Johnson
Debra Dixon
Chief of staff to Rep. Xavier Becerra, legislative director to Rep. Becerra, legislative counsel to Rep. Becerra, chief of staff, Office of Policy and Planning, U.S. Department of Education, Immigration Counsel, U.S. Department of Justice.
Michael Taggart
Energy and Commerce Committee --Policy Director; Rep. Cathy McMorris Rodgers -- Legislative Director; Rep. Leonard Lance-- Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on April 21.
Original Filing: 301569483.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
4th Quarter, 2023
In Q4, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on Jan. 21.
Original Filing: 301534996.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
3rd Quarter, 2023
In Q3, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on Oct. 19, 2023.
Original Filing: 301509245.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
2nd Quarter, 2023
In Q2, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on July 20, 2023.
Original Filing: 301489738.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
1st Quarter, 2023
In Q1, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on April 20, 2023.
Original Filing: 301466470.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
4th Quarter, 2022
In Q4, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on Jan. 20, 2023.
Original Filing: 301443464.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
3rd Quarter, 2022
In Q3, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413417.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
2nd Quarter, 2022
In Q2, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on July 20, 2022.
Original Filing: 301395868.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
1st Quarter, 2022
In Q1, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on April 20, 2022.
Original Filing: 301371512.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to the pharmaceutical supply chain. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
4th Quarter, 2021
In Q4, FEROX STRATEGIES lobbied for Viatris Inc. , earning $70,000. The report was filed on Jan. 20, 2022.
Original Filing: 301336749.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to the pharmaceutical supply chain. Issues related to drug pricing. Issues related to FDA generic drug approval process.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
3rd Quarter, 2021
In Q3, FEROX STRATEGIES lobbied for Viatris Inc. , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301310208.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to the pharmaceutical supply chain. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
FEROX STRATEGIES amended a lobbying report for representation of Viatris Inc. in Q22021 on Oct. 15, 2021.
Original Filing: 301299828.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to the pharmaceutical supply chain. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
In Q2, FEROX STRATEGIES lobbied for Viatris Inc. , earning $40,000. The report was filed on July 20, 2021.
Original Filing: 301288161.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to the pharmaceutical supply chain. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2021
In Q1, FEROX STRATEGIES lobbied for Viatris Inc. , earning $40,000. The report was filed on April 20, 2021.
Original Filing: 301263754.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry. Issues related to the pharmaceutical supply chain. Issues related to drug pricing. Issues related to FDA generic drug approval process. Issues related to federal COVID-19 response. General issues related to Agriculture Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2020
FEROX STRATEGIES amended a lobbying report for representation of Viatris Inc. (formerly Mylan Inc.) in Q42020 on Jan. 21, 2021.
Original Filing: 301242923.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
Issues related to the pharmaceutical supply chain
Issues related to drug pricing
Issues related to FDA generic drug approval process
Issues related to Medicaid Generics Penalty
Issues related to federal COVID-19 response
S.4134 - A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program
Issues related to the consumer price index
H.R. 6395/S. 4049 - FY 2021 National Defense Authorization Act
H.R.133 - Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Executive Office of the President (EOP)
4th Quarter, 2020
In Q4, FEROX STRATEGIES lobbied for Viatris (formerly Mylan Inc.) , earning $40,000. The report was filed on Jan. 19, 2021.
Original Filing: 301234545.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
Issues related to the pharmaceutical supply chain
Issues related to drug pricing
Issues related to FDA generic drug approval process
Issues related to Medicaid Generics Penalty
Issues related to federal COVID-19 response
S.4134 - A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program
Issues related to the consumer price index
H.R. 6395/S. 4049 - FY 2021 National Defense Authorization Act
H.R.133 - Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Executive Office of the President (EOP)
3rd Quarter, 2020
In Q3, FEROX STRATEGIES lobbied for Mylan Inc. , earning $40,000. The report was filed on Oct. 20, 2020.
Original Filing: 301218161.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
Issues related to the pharmaceutical supply chain
Issues related to drug pricing
Issues related to FDA generic drug approval process
Issues related to Medicaid Generics Penalty
Issues related to federal COVID-19 response
S.4134 - A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program
Issues related to the consumer price index
H.R. 6395/S. 4049 - FY 2021 National Defense Authorization Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Executive Office of the President (EOP)
2nd Quarter, 2020
In Q2, FEROX STRATEGIES lobbied for Mylan Inc. , earning $40,000. The report was filed on July 20, 2020.
Original Filing: 301199565.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Executive Office of the President (EOP)
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the pharmaceutical supply chain
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Executive Office of the President (EOP)
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to drug pricing
Issues related to Medicaid Generics Penalty
S.4134 - A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program
Consumer price index
Issues related to workplace health and safety
Issues related to the pharmaceutical supply chain
H.R. 6395/S. 4049 - FY 2021 National Defense Authorization Act
Issues related to federal COVID-19 response
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Executive Office of the President (EOP)
1st Quarter, 2020
In Q1, FEROX STRATEGIES lobbied for Mylan Inc. , earning $40,000. The report was filed on April 20, 2020.
Original Filing: 301178026.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
H.R.965/S. 340 - CREATES Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to intellectual property in the United States-Mexico-Canada Agreement
S.3538 - Strengthening America's Supply Chain and National Security Act
H.R.6201 - Families First Coronavirus Response Act
H.R.748 - CARES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to drug pricing
H.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019
H.R.938 - BLOCKING Act of 2019
H.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act
H.R.965/S. 340 - CREATES Act of 2019
H.R.2375/S. 64 - Preserve Access to Affordable Generics and Biosimilars Act
H.R.2374/S. 1224 - Stop STALLING Act
S.1895 - Lower Health Care Costs Act
S.2103 - Affordable Insulin Approvals Now Act
S.474 - Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act
S.1416 - Affordable Prescriptions for Patients Act of 2019
H.R.1865 - Further Consolidated Appropriations Act, 2020
H.R.4913 - To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
H.R.6179 - Increasing Access to Biosimilars Act of 2020
H.R.6201 - Families First Coronavirus Response Act
H.R.748 - CARES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, FEROX STRATEGIES lobbied for Mylan Inc. , earning $30,000. The report was filed on Jan. 21, 2020.
Original Filing: 301125472.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
H.R.965/S. 340 - CREATES Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to intellectual property in the United States-Mexico-Canada Agreement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to drug pricing
H.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019
H.R.938 - BLOCKING Act of 2019
H.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act
H.R.965/S. 340 - CREATES Act of 2019
H.R.2375/S. 64 - Preserve Access to Affordable Generics and Biosimilars Act
H.R.2374/S. 1224 - Stop STALLING Act
S.1895 - Lower Health Care Costs Act
S.2103 - Affordable Insulin Approvals Now Act
S.474 - Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act
S.1416 - Affordable Prescriptions for Patients Act of 2019
H.R.1865 - Further Consolidated Appropriations Act, 2020
H.R.4913 - To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
In Q3, FEROX STRATEGIES lobbied for Mylan Inc. , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301075808.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
H.R.965/S. 340 - CREATES Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to intellectual property in the United States-Mexico-Canada Agreement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to drug pricing
H.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019
H.R.938 - BLOCKING Act of 2019
H.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act
H.R.965/S. 340 - CREATES Act of 2019
H.R.2375/S. 64 - Preserve Access to Affordable Generics and Biosimilars Act
H.R.2374/S. 1224 - Stop STALLING Act
S.1895 - Lower Health Care Costs Act
S.2103 - Affordable Insulin Approvals Now Act
S.474 - Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2019
In Q2, FEROX STRATEGIES lobbied for Mylan Inc. , earning $30,000. The report was filed on July 22, 2019.
Original Filing: 301056388.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
H.R.965/S. 340 - CREATES Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to intellectual property in the United States-Mexico-Canada Agreement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to drug pricing
H.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019
H.R.938 - BLOCKING Act of 2019
H.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act
H.R.965/S. 340 - CREATES Act of 2019
H.R.2375/S. 64 - Preserve Access to Affordable Generics and Biosimilars Act
H.R.2374/S. 1224 - Stop STALLING Act
S.1895 - Lower Health Care Costs Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2019
In Q1, FEROX STRATEGIES lobbied for Mylan Inc. , earning $30,000. The report was filed on April 22, 2019.
Original Filing: 301036837.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
H.R.965/S. 340 - CREATES Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to intellectual property in the Unites States-Mexico-Canada Agreement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to drug pricing
S.474 - Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
H.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019
H.R.938 - BLOCKING Act of 2019
H.R.1520 - Purple Book Continuity Act of 2019
H.R.1503 - Orange Book Transparency Act of 2019
H.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes
S.64 - Preserve Access to Affordable Generics and Biosimilars Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2018
In Q4, FEROX STRATEGIES lobbied for Mylan Inc. , earning $20,000. The report was filed on Jan. 22, 2019.
Original Filing: 301016389.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
H.R.2212/S. 974 - CREATES Act of 2017
H.R. 7251/S.3738 - Hatch-Waxman Integrity Act of 2018
H.R.6294 - REVAMP Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to intellectual property in the North American Free Trade Agreement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2018
In Q3, FEROX STRATEGIES lobbied for Mylan Inc. , earning $20,000. The report was filed on Oct. 22, 2018.
Original Filing: 300996067.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
H.R.2212/S. 974 - CREATES Act of 2017
Hatch-Waxman Integrity Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to intellectual property in the North American Free Trade Agreement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2018
In Q2, FEROX STRATEGIES lobbied for Mylan Inc. , earning $20,000. The report was filed on July 20, 2018.
Original Filing: 300975681.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
H.R.2212/S. 974 - CREATES Act of 2017
Hatch-Waxman Integrity Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2018
In Q1, FEROX STRATEGIES lobbied for Mylan Inc. , earning $10,000. The report was filed on April 20, 2018.
Original Filing: 300953229.xml
Lobbying Issues
Policy and oversight related to the generic pharmaceutical industry
H.R.2212/S. 974 - CREATES Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Health Issues Copyright/Patent/Trademark
1st Quarter, 2018
FEROX STRATEGIES filed a lobbying registration on March 16, 2018 to represent Mylan Inc., effective March 1, 2018.
Original Filing: 300941598.xml
Issue(s) they said they’d lobby about: Policy and oversight related to the generic pharmaceutical industry. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate